Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates

Kailera reported a Q3 2026 net loss of $95.7 million with $1.04 billion in cash and runway into mid-2028. All four pipeline candidates hit their milestones: ribupatide injection Phase 2b and the ~5,000-participant KaiNETIC Phase 3 program are fully enrolled (data mid-2027 and mid-2028), oral ribupatide cleared its End-of-Phase 2 FDA meeting for a 1H 2027 Phase 3 start, safiglipron Phase 2 data moved to mid-2027, and the KAI-4729 IND is active with a Phase 1 trial expected to begin by end of 2026.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.